Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

This Government Contract opportunity from Department Of Health And Human Services was posted on August 7, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

PRISM Cancer Cell Line Drug Sensitivity Study

Closed
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

AI Contract Overview

Show more

The contract calls for the execution of a high-throughput PRISM study to assess the drug sensitivity of compound NCGC01219867 across approximately 900 barcoded cancer cell lines using a Luminex-format assay with a 5-day exposure period and an 8-point dose-response dilution series. This effort is designed to generate comprehensive pharmacological profiles for the compound across a broad panel of genetically diverse cancer models, enabling the identification of sensitive and resistant lines, potential biomarkers of response, and differential activity patterns by lineage. The work involves precise handling of cell lines, standardized dosing protocols, and high-precision data collection through the Luminex platform to ensure reproducibility and statistical power across the large-scale screening effort. The initiative is issued as a subcontract under the National Institutes of Health, part of the Department of Health and Human Services, with a NAICS code of 541715 indicating classification under research and development in the physical, engineering, and life sciences. The solicitation was posted on August 7, 2026, with a response deadline of August 24, 2026, and the place of performance is unspecified, suggesting flexibility in location provided the technical requirements are met. There is no set-aside designation or point of contact listed, and the work is focused entirely on experimental execution rather than broader administrative or clinical development tasks.

General Info

PRISM study testing NCGC01219867 on 900 cancer lines via Luminex assay with 8-point dose response over 5 days.

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

MD

Set-Aside

NONE

Documents

This scope was carved out of 75N98026Q00990.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

PRISM study of a Compound NCGC01219867

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed
Posted

subcontract

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao
ContactsNo contacts available
OfficeN/A
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Conduct a high-throughput PRISM study to evaluate the drug sensitivity of compound NCGC01219867 across approximately 900 barcoded cancer cell lines using a 5-day Luminex-format assay with an 8-point dose-response dilution series.

More opportunities from Department Of Health And Human Services → National Institutes Of Health Olao

Same awarding agency

Earlier notices in this NAICS code

Posted before this notice, open and closed

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS